Korrik 2022: Sipas hulumtimit më të fundit të kryer nga Emergen Research, tregu global për terapinë e qelizave T CAR arriti një madhësi prej 1.29 miliardë dollarë në vitin 2021 dhe pritet të regjistrojë një CAGR prej 24.9 përqind gjatë periudhës së parashikimit. Rritja e incidencës së kancerit në të gjithë botën, si dhe shkalla në rritje e vdekshmërisë së shkaktuar nga kanceri pritet të jenë nxitësit kryesorë të rritjes së të ardhurave në tregun global të terapisë me qeliza CAR-T gjatë periudhës së parashikimit. Zgjerimi i aktiviteteve të provave klinike me një ritëm marramendës, përhapja e bashkimeve dhe blerjeve dhe joshja e ofertave publike fillestare janë të gjithë faktorë që po kontribuojnë në rritjen e të ardhurave në tregun global të terapisë me qeliza T CAR.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapia me qeliza T CAR market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapia me qeliza T CAR market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Gjetje të tjera të rëndësishme nga raporti tregojnë se
In 2021, the segment of diffuse large B-cell limfome was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with terapia e qelizave T të receptorit kimerik të antigjenit, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell non-Hodgkin lymphomas who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Kompanitë kryesore që operojnë aktualisht në treg janë hetuar më tej në këtë raport, si dhe profilet e tyre të kompanive, portofolet e produkteve, strategjitë e zgjerimit dhe aleancat strategjike. Disa shembuj të këtyre llojeve të aleancave përfshijnë bashkimet dhe blerjet, bashkëpunimet dhe sipërmarrjet e përbashkëta. Përveç kësaj, ai ofron pika kryesore në lidhje me arritjet e kompanisë dhe gjendjen financiare, si dhe njohuri mbi shtrirjen e tregut dhe pozicionin global të kompanisë.
Kompanitë e profilizuara në tregun global të CAR T-Cell Therapy:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. dhe Eli Lilly and Company .
Lexoni më shumë mbi raportin global të tregut të CAR T-Cell Therapy në: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
